Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DROP-FPF: Nerandomilast in familial pulmonary fibrosis risk with interstitial lung abnormalities
2025-522383-33-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis (PF) and interstitial lung disease (ILD) comparing Nerandomilast (BI 1015550) with Placebo (2 arms). Primary endpoint: Time to physiologic or radiologic worsening of ILA/ILD over the whole trial. Planned start Mar 2026; status: authorised.
02
Drugs
nerandomilast
03
Conditions
pulmonary fibrosis (PF)interstitial lung disease (ILD)
Beyond the preview
Go deeper on 2025-522383-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522383-33-00.